SCS
ABCL icon

Syquant Capital SAS’s AbCellera Biologics ABCL Stock Holding History

Syquant Capital SAS’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-70,000
Closed -$1.54M – 43
2021
Q2 		$1.54M Buy
+70,000
New +$1.93M 1.85% 15

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Syquant Capital SAS's ABCL Position: Q3 2021 in Review

Syquant Capital SAS sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 70,000 shares — an estimated $1.54M sold.

Syquant Capital SAS first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $1.54M in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • Syquant Capital SAS reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • Syquant Capital SAS sold 70,000 AbCellera Biologics shares in Q3 2021, an estimated $1.54M.
  • Syquant Capital SAS first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
  • Syquant Capital SAS's AbCellera Biologics position peaked at $1.54M in Q2 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on Syquant Capital SAS's 13F filing for Q3 2021, filed 14 Oct 2021.